Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study investigates the effect of vildagliptin, an inhibitor of the enzyme DPP-4, on the
cognitive functioning of elderly diabetic patients with mild cognitive impairment (MCI)
documented at mini mental state examination (MMSE).
In this prospective study, 60 diabetic elderly people were enrolled and divided according to
their glycated hemoglobin (HbA1c) values in 2 groups: Group A, (HbA1c <7.5%, n=30) treated
with metformin, and Group B (HbA1c >7.5%, n=30) treated with metformin plus vildagliptin. We
evaluated MMSE, fasting plasma glucose (FPG) and HbA1c at baseline and after 24 weeks
treatment.